Deorphaning GPR149: A testable framework and integrated roadmap for a neuro-metabolic orphan GPCR

Background: The ”dark GPCRome”—orphan GPCRs with unknown ligands—represents untapped therapeutic potential. GPR149, found in metabolic and reward circuits, illustrates this challenge despite being an orphan for over 20 years. Purpose: To propose a testable mechanistic framework for GPR149 and outline an integrated deorphanization strategy that acts as a template for systematic orphan receptor discovery. Conclusion: GPR149 likely acts as a Gi/o-coupled inhibitory modulator with inherent activity, affecting both neuronal circuits and oligodendrocyte precursor differentiation. A coordinated four-pillar strategy that includes high-throughput screening, structural biology, AI-driven chemistry, and circuit validation can quickly clarify its role, establishing GPR149 as a model dual-domain neuro-metabolic target. 1. Introduction: The Case for Prioritizing GPR149 in the Dark GPCRome The ”dark GPCRome”—orphan GPCRs with unknown endogenous ligands—represents a major untapped reservoir of therapeutic targets. Historically, deorphanization relied on serendipity. Today, however, converging technologies—including cryo‑electron microscopy (cryo‑EM), multiplexed functional assays, and AI‑driven ligand discovery—enable systematic, hypothesis‑driven campaigns [1,2]. Among these orphans, GPR149 stands out as a compelling prototype. Its mRNA is detected in key brain regions governing energy balance and reward processing, including the arcuate and ventromedial hypothalamus, nucleus accumbens, and islands of Calleja [4,5]. Gpr149‑null mice display altered energy homeostasis and improved insulin sensitivity [6], while its sequence conservation suggests a non‑redundant physiological role. Notably, GPR149 is also expressed in oligodendrocyte precursor cells (OPCs), where its deletion accelerates differentiation and remyelination—the receptor’s most directly validated function to date [7]. Despite these clues, GPR149 remains an orphan two decades after its discovery [3], with its signalling mechanism, endogenous ligand, and circuit‑level functions unknown. Here, we argue that GPR149 is an ideal test case for modern deorphanization strategies. We propose a testable mechanistic framework centred on predicted Gi/o coupling and constitutive activity, and outline an integrated, four‑pillar roadmap to systematically resolve its biology—a template that could accelerate discovery across the dark GPCRome. 2. A Testable Mechanistic Framework for GPR149 Signaling The absence of an identified endogenous ligand makes GPR149 a pharmacological blank slate—but not an empty one. Bioinformatic predictions, structural motifs, and indirect phenotypic evidence converge on a compelling, testable model: GPR149 likely operates as a Gi/o‑coupled receptor with constitutive activity, exerting inhibitory control across both neuronal and glial circuits. While these inferences remain provisional until biochemical validation, they provide a crucial scaffold for directing experimental efforts and separating established facts from mechanistic speculation. 2.1 Predicted Gi/o Coupling: Placing a Brake on Neuronal Excitability Sequence analysis reveals that GPR149 contains canonical class A GPCR motifs—including the DRY and NPxxY micro-switches necessary for activation [8,11]. While these motifs alone do not specify G-protein coupling, their presence, combined with broader sequence homology and residue patterns in intracellular loops characteristic of Gi/o-coupled receptors, provides a testable prediction for its primary signaling pathway [8]. If confirmed, this coupling would position GPR149 as an inhibitory neuromodulator, suppressing adenylate cyclase, reducing intracellular cAMP, and modulating ion channels such as G protein‑gated inwardly rectifying potassium (GIRK) channels and voltage‑gated calcium channels [9]. Why does this matter for GPR149’s therapeutic potential? Its expression pattern provides the answer. In the hypothalamus, Gi/o‑mediated inhibition could modulate AgRP or POMC neurons, influencing satiety and energy expenditure. In the nucleus accumbens and related reward circuits, the same signaling logic might dampen dopaminergic or glutamatergic transmission, thereby altering motivational drive and reward valuation. These circuit‑level hypotheses remain untested—but they are now directly testable using cAMP biosensors, electrophysiology, and cell‑type‑specific manipulations. 2.2 Constitutive Activity: A Pharmacologically Actionable Hypothesis The metabolic phenotype of Gpr149 ‑null mice—altered energy balance and improved insulin sensitivity [6]—hints at a receptor with baseline physiological tone. One parsimonious explanation is that GPR149 exhibits constitutive (ligand‑independent) activity, a common feature among class A Gi/o‑coupled receptors that maintain a steady inhibitory brake on signaling pathways [10]. This hypothesis carries immediate pharmacological implications. If GPR149 is constitutively active, a neutral antagonist would have little effect, whereas an inverse agonist could suppress baseline signaling and potentially replicate the metabolic benefits seen in Gpr149 -null mice [6]. However, it is crucial to consider alternative models. The observed phenotype could equally arise from the absence of signaling induced by a conditionally present endogenous ligand—for instance, one released during states of positive energy balance. Distinguishing between these models (constitutive activity vs. ligand-dependent tone) is a primary objective of the proposed deorphanization roadmap, as each would favor a different initial pharmacological strategy (inverse agonist vs. neutral antagonist). Broader alternative explanations—such as developmental compensation—must also be ruled out using inducible knockout models, but the constitutive activity framework provides a clear, testable, and pharmacologically actionable starting point. Together, these bioinformatic, phenotypic, and structural predictions form a cohesive and actionable model for GPR149 (summarized in Figure 1 ), transforming it from a molecular enigma into a systematically addressable prototype for orphan receptor discovery. Figure 1. GPR149 Expression Patterns and Current Evidence Status (A) Sagittal view of a mouse brain highlighting regions with detected GPR149 mRNA expression, based on single-cell transcriptomic atlases [4,5]. Color intensity reflects relative expression levels. Key regions include hypothalamic nuclei involved in energy balance (arcuate, ARC; ventromedial, VMH), striatal areas central to reward processing (nucleus accumbens, NAc; islands of Calleja, ICj), and limbic structures. (B) Evidence matrix for GPR149. While its expression profile is established, fundamental aspects of its pharmacology and physiology—including G-protein coupling, signaling mechanism, endogenous ligand, circuit function, and disease relevance—remain unknown or predicted. (C) Cellular context of GPR149 expression. While its function in neurons (left) is speculative, a validated role has been demonstrated in oligodendrocyte precursor cells (OPCs, right). GPR149 acts as a negative regulator of OPC differentiation; its deletion accelerates maturation and remyelination via the MAPK/ERK pathway [10], representing the most direct functional characterization to date. 2.3 Ligand Class Considerations: Why Agnostic Screening is Essential GPR149’s relatively large extracellular N‑terminal domain is a structural feature associated with peptide‑binding capability in certain Class A GPCR subfamilies [11], while phylogenetic analyses point toward lipid‑sensing ancestry. This structural duality means the endogenous ligand could belong to multiple classes—making broad, agnostic screening essential. Initial functional screens should therefore interrogate diverse libraries spanning peptides, lipids, metabolites, and synthetic small molecules to maximize the chance of identifying even a low‑potency surrogate ligand. These competing structural clues, together with the predicted Gi/o signaling cascade and constitutive activity framework, are synthesized in Figure 2, providing a visual roadmap for the testable hypotheses that drive the deorphanization strategy forward. Figure 2. Predicted Signaling Mechanisms and Testable Hypotheses for GPR149 (A) Predicted structural features of GPR149. The receptor exhibits a canonical Class A GPCR topology consisting of seven transmembrane helices and a relatively large extracellular N-terminal domain (light blue). Conserved sequence motifs (DRY, NPxxY; highlighted in red) serve as established micro-switches for G-protein coupling and receptor activation across the Rhodopsin family. While these motifs are statistically associated with specific signaling states, their functional role in GPR149 remains a prediction pending validation. Note: Figure 2 is a conceptual representation of hypothesized mechanisms; motifs are highlighted for illustrative purposes and are not derived from primary crystallographic or experimental data. (B) Hypothesized Gi/o-mediated signaling cascade . If Gi/o coupling is confirmed, GPR149 activation would be predicted to inhibit adenylyl cyclase (AC), reduce intracellular cAMP, activate G protein-gated inwardly rectifying potassium (GIRK) channels to hyperpolarize the membrane, and inhibit voltage-gated calcium (Cav) channels to suppress neurotransmitter release. All components of this signaling model require direct experimental validation. (C) The constitutive activity hypothesis. The metabolic phenotype of Gpr149 -null mice [6] could be explained if the receptor exhibits ligand-independent (constitutive) signaling (left). This would have direct pharmacological implications, favoring inverse agonists to suppress baseline activity. However, alternative explanations—including a conditional, high-tone endogenous ligand, developmental compensation, or non-canonical functions—must be ruled out experimentally. 2.4 A Putative Role in Neuronal Plasticity GPR149 is expressed in plasticity‑rich regions like the striatum and hypothalamus. Through Gi/o‑mediated reductions in cAMP, it could influence long‑term synaptic remodeling via downstream effectors such as CREB, which regulates synaptic protein synthesis and cytoskeletal reorganization [12]. This raises the provocative possibility that GPR149 modulation might drive sustained changes in circuit function—impacting not only acute metabolic responses but also long‑term behavioral adaptations. 2.5 Oligodendrocyte Precursor Cells: Expanding GPR149’s Functional Horizon Beyond neurons, GPR149 is functionally active in oligodendrocyte precursor cells (OPCs), where its deletion accelerates differentiation and remyelination via the MAPK/ERK pathway [7]. This glial role extends GPR149’s potential therapeutic reach into structural plasticity and white‑matter repair, suggesting that ligands could influence both circuit‑level activity and myelin integrity—a dual mechanism rarely seen in single GPCR targets. 3. A Contemporary Roadmap for Deorphanizing GPR149 The era of serendipitous GPCR deorphanization is over. Today, converging technologies enable a parallel, integrated campaign that can systematically transform an orphan like GPR149 from mystery to mechanism. The goal is no longer merely to find a ligand, but to rapidly map its signaling architecture, structural blueprint, and circuit‑level functions—a coordinated approach that could compress years of incremental research into a focused discovery sprint. 3.1 Pillar I: High‑Throughput Functional Screening—Cast a Wide Net The first move is agnostic, high‑throughput screening. Primary assays must be both sensitive and broad. Given the predicted Gi/o coupling, cAMP inhibition assays can detect ligand‑induced responses while also measuring baseline constitutive activity. These should be complemented by pathway‑agnostic readouts like the PRESTO‑Tango β‑arrestin recruitment system [14], which catches activators irrespective of G‑protein preference. Library diversity is non‑negotiable. Screens should interrogate peptides, lipids, metabolites, and synthetic small molecules. Even a low‑potency hit provides a crucial foothold—a chemical tool to stabilize the receptor for structural studies and refine subsequent screening rounds. 3.2 Pillar II: Structural Biology—A Blueprint for Rational Design Single‑particle cryo‑EM has transformed GPCR structural biology, making high‑resolution models of orphan receptors attainable [15]. For GPR149, a structural snapshot—whether apo or stabilized by a weak ligand or nanobody—would be transformative. An inactive‑state structure would reveal the orthosteric pocket architecture and the conformation of the extended N‑terminal domain, offering decisive clues about ligand class. It would also spotlight potential allosteric sites, laying groundwork for next‑generation drug design. This structural blueprint creates a powerful feedback loop with functional screening data, accelerating ligand identification and optimization. 3.3 Pillar III: AI‑Enabled Generative Chemistry—Designing from the Ground Up With a structural model in hand, AI‑driven ligand discovery can explore chemical space at unprecedented scale. Structure‑based virtual screening can prioritize candidates from multimillion‑compound libraries, while generative AI models can build novel scaffolds optimized for binding affinity, synthetic feasibility, and even biased signaling profiles (e.g., Gi/o versus β‑arrestin bias). The caveat: Computational success hinges on structural accuracy, especially for GPR149’s flexible extracellular domain. If the N‑terminus proves disordered without ligand, AI efforts may require iterative refinement with new experimental data. Nevertheless, this pillar shifts the goal from finding a ligand to designing one with tailored pharmacological properties. 3.4 Pillar IV: Circuit‑Level Validation—From Molecules to Behavior The ultimate test of any GPR149 ligand occurs in vivo. A circuit‑level validation program should run in parallel with molecular discovery, using chemogenetic (e.g., DREADDs) and optogenetic tools to mimic receptor activation or inhibition in GPR149‑expressing neurons within hypothalamus, nucleus accumbens, and VTA [17]. Behavioral readouts must capture GPR149’s dual domains: metabolic assays (feeding, energy expenditure) alongside motivational and affective measures (effort‑based choice, reward conditioning, stress responsivity). This integrated approach ensures that functional consequences are understood at the systems level from the outset. Together, these four pillars form an iterative, synergistic engine (summarized in Figure 3 )—not a linear pipeline, but a feedback‑rich discovery cycle designed to deliver value even if the “perfect” ligand proves elusive. Figure 3. An Integrated, Iterative Pipeline for the Systematic Deorphanization of GPR149 A proposed multi-pronged strategy to resolve GPR149’s biology, structured around four synergistic pillars that operate in parallel with iterative feedback. Pillar I: Foundational Biology (Year 1). Initial priorities include definitive determination of G-protein coupling (e.g., via BRET-based biosensors), assessment of constitutive activity, and high-resolution mapping of cell-type-specific expression. Pillar II: Ligand Discovery (Years 1–3). Agnostic, high-throughput functional screening against diverse chemical libraries (peptides, lipids, metabolites) is complemented by structural biology (cryo-EM) and AI-driven de novo ligand design to identify and optimize tool compounds. Pillar III: Circuit Validation (Years 2–4). Functional roles are probed in native circuits using chemogenetic (DREADDs) and conditional knockout approaches, with behavioral readouts spanning metabolic, motivational, and affective domains. Pillar IV: Tiered Outcome Framework. The strategy defines success broadly: optimal success (Tier 1) yields a high-affinity ligand with full mechanistic understanding; partial success (Tier 2) provides key signaling and circuit insights even without a ligand; productive failure (Tier 3) generates methodological advances and refined prioritization criteria for the broader dark GPCRome. This framework ensures the campaign delivers value across multiple possible outcomes. The graphical abstract is a conceptual visualization generated using AI-assisted design tools based on the author’s theoretical framework and mapped circuitry. 4. GPR149 as a Dual‑Domain Target: Learning from the Incretin Precedent GPR149’s therapeutic appeal lies in a “dual‑domain” strategy: the ability to modulate both metabolic and psychiatric functions through a single pharmacological target. The incretin paradigm—exemplified by GLP‑1 receptor agonists—provides a powerful roadmap for such targets [7]. This analogy is primarily functional and anatomical; while GLP-1R is a Class B GPCR and GPR149 is Class A—entailing distinct mechanisms of ligand engagement and activation—both receptors converge functionally on key hypothalamic and striatal circuits. 4.1 The Incretin Paradigm: From Glucose Control to Neural Rewiring GLP‑1R agonists were originally developed for type 2 diabetes, targeting peripheral glucose regulation. Their most transformative clinical impact, however, emerged from central actions on appetite, reward processing, and affective state [7]. This expansion from a purely metabolic target to a neuro‑metabolic modulator illustrates a critical principle: receptors that bridge somatic and motivational physiology can deliver therapeutic benefits far beyond initial indications. The incretin story also highlights that lasting efficacy may stem from drug‑induced neuroplasticity—rewiring maladaptive circuits—rather than acute metabolic changes alone. This shift from viewing such agents as mere appetite suppressants to recognising them as modulators of adaptive neural restructuring provides a compelling model for GPR149. 4.2 Anatomical and Functional Parallels GPR149 displays striking overlaps with the incretin blueprint. Transcriptomic data place it in key GLP‑1R‑expressing regions, including the arcuate and ventromedial hypothalamus, nucleus accumbens, and limbic structures. Functionally, its predicted Gi/o coupling suggests a dampening of neuronal excitability that parallels the net inhibitory influence of GLP‑1R activation on reward‑related transmission. Moreover, GPR149’s potential role in cAMP‑mediated synaptic remodeling offers a plausible substrate for sustained behavioural effects, mirroring evidence that GLP‑1R agonists induce durable neural adaptations. This convergence suggests GPR149 is strategically positioned to influence feeding, reward‑seeking, and motivational drive through similar circuit nodes. 4.3 Beyond Neurons: The Oligodendrocyte Advantage A key distinction—and potential advantage—for GPR149 is its validated role in glial cells. Unlike GLP‑1R, GPR149 is expressed in oligodendrocyte precursor cells (OPCs) and suppresses their differentiation and remyelination [13]. This expands its therapeutic canvas to include structural plasticity and white‑matter integrity. Consequently, a GPR149 ligand could influence both circuit function and myelination, broadening its potential beyond metabolic and psychiatric disorders to demyelinating diseases—a domain outside current incretin therapies and one that significantly enhances its clinical applicability. 4.4 Strategic Implications for Discovery Treating GPR149 a priori as a dual‑domain target shapes a discovery programme with built‑in advantages: • Rational Pipeline Design: Early behavioural assays can capture subtle, cross‑domain efficacy that single‑focus screens might miss. • Bias Engineering: Ligands can be designed for specific signalling biases (e.g., Gi/o vs. β‑arrestin) to potentially separate metabolic, motivational, and glial‑modulating effects. • Broad Therapeutic Potential: This approach maximises the chance of discovering compounds with utility across a spectrum of conditions—from overeating and addiction to demyelinating diseases. • Risk Mitigation: The integrated, parallel‑track roadmap ensures that even if ligand discovery stalls, structural and circuit‑level insights continue to deliver fundamental biological value. These factors establish GPR149 as a prototype for next‑generation GPCR targets, whose value is measured not by a single isolated function but by their integrated role across physiological domains. 5. An Integrated Path Forward: From Pharmacology to Circuitry Translating GPR149 modulation into predictable behavioural outcomes demands more than biochemical profiling—it requires circuit‑aware pharmacology. Three principles should guide this integration: 1. Circuit Architecture Determines Functional Impact. A ligand’s effect depends not only on its signalling bias (e.g., Gi/o versus β‑arrestin) but on how that signalling propagates through specific neural populations. Mapping GPR149’s actions to defined hypothalamic, striatal, and limbic circuits is therefore essential. 2. Biased Agonism Offers a Path to Functional Specificity. Ligands with different bias profiles could unlock distinct physiological effects: a Gi/o‑biased compound might drive acute metabolic changes, while an arrestin‑biased ligand that promotes internalisation might favour long‑term remodelling of reward circuits. Bias should be quantified early in ligand characterisation. 3. Multimodal Validation De‑risks Translation. Chemogenetic surrogates (e.g., DREADDs) can probe circuit‑specific roles before high‑affinity ligands exist ; optogenetics provides causal, temporally precise validation; computational modelling can decipher effects on decision‑making and reward valuation. Together, these approaches bridge receptor biophysics and whole‑animal behaviour, reducing translational uncertainty. 6. Strategic Prioritization and Risk Mitigation With over 100 orphan GPCRs vying for attention, justifying focus on GPR149 requires a compelling, multi‑faceted case. 6.1 Why GPR149 Earns Priority Four pillars distinguish GPR149 from typical orphans: 1. Anatomically Strategic Expression – It localises to hypothalamic, striatal, and limbic hubs that integrate metabolic, motivational, and emotional processing. 2. Non‑redundant Physiological Role – Gpr149 ‑null mice display altered energy balance and improved insulin sensitivity [6], confirming systemic relevance. 3. Evolutionary Conservation & Tractability – Conserved motifs signal essential function and improve prospects for structural studies. 4. Dual Neuronal–Glial Function – Its validated role in OPC differentiation and remyelination [13] reveals a second therapeutic axis rarely seen in orphan GPCRs. Together, these pillars frame GPR149 not as a curiosity but as a high‑value regulator with plausible, multi‑system impact. 6.2 A Practical Risk‑Mitigation Framework Orphan‑receptor campaigns are inherently uncertain, but risks can be managed: • Parallel‑Track Discovery – Concurrent cryo‑EM, screening, and circuit assays prevent single‑point failures. • Early Surrogate Tools – Chemogenetics and CRISPR‑based manipulations yield circuit‑level insights before a ligand is in hand. • Agnostic Screening – Libraries spanning peptides, lipids, and small molecules avoid presupposing ligand class. • Rapid Ligand Prototyping – AI‑driven design, even of modest‑potency scaffolds, can quickly test therapeutic hypotheses. • Cross‑Species Validation – Comparative genomics ensures relevance to human biology. This layered strategy transforms GPR149 from a speculative venture into a manageable, high‑reward discovery programme. 7. Concluding Remarks: A Prototype for the Dark GPCRome GPR149 embodies a class of orphan GPCRs that are therapeutically tantalizing yet技术上 tractable. Its precise expression, predicted Gi/o inhibitory signalling, hypothesized constitutive activity, and verified dual neuronal–glial functions make it an ideal prototype for modern deorphanization. The integrated roadmap presented here—synergising high‑throughput screening, cryo‑EM, AI‑driven chemistry, and circuit validation—provides a concrete blueprint to accelerate its transition from orphan to characterised target. Success would not only illuminate a new regulatory node at the metabolic‑motivational‑affective intersection but also deliver pharmacological tools for probing neural circuit plasticity. Beyond GPR149, this approach establishes a reproducible model for prioritising and de‑risking other high‑value orphans. As technologies mature, focused campaigns on such prototypes can systematically illuminate the dark GPCRome, bringing its most promising targets into the therapeutic spotlight. Competing Interests The author declares no competing interests. Author Contributions M.A.S.G. conceived the article, performed the literature review, developed the mechanistic framework, wrote the manuscript, and approved the final version. Funding No external funding was received for the preparation of this manuscript. Declaration of Generative AI and AI-Assisted Technologies in the Writing Process During the preparation of this work, the author used OpenAI’s ChatGPT and DeepSeek to provide editorial assistance, improve language clarity, and assist with manuscript organization. Additionally, the conceptual schematics in Figures 1, 2, 3, and the Graphical Abstract Image were generated using Google’s Gemini 3 suite based on detailed functional prompts and theoretical frameworks provided by the author. After using these tools, the author critically reviewed, refined, and edited all output, including schematic accuracy. The author takes full responsibility for the original scientific content and the final integrity of the manuscript.

N/A.

1. Roth BL, Shoichet BK. Mining the dark GPCRome for new therapeutic targets. Nat Rev Drug Discov . 2023;22:89-106. 2. Hauser AS, Attwood MM, Rask-Andersen M, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov . 2017;16:829-842. 3. De Smet C, Lurquin C, Lethé B, et al. A novel seven-transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. J Neurochem . 2002;81:575-588. 4. Zhang M, Pan X, Jung W, et al. A molecularly defined and spatially resolved cell atlas of the whole mouse brain. Nature . 2023;616:133-142. 5. Siletti K, Hodge R, Albiach AM, et al. Transcriptomic diversity of cell types across the adult human brain. Science . 2023;382:eadd7046. 6. Wyler SC, Gachon F, Lang RA. Gpr149 is involved in energy homeostasis in the male mouse. PeerJ . 2024;12:e16739. 7. Suo N, Guo YE, He B, et al. The orphan G protein-coupled receptor GPR149 is a negative regulator of myelination and remyelination. Glia . 2022;70:1992-2008. 8. Inoue A, Raimondi F, Kadji FMN, et al. Illuminating G protein-coupling selectivity of GPCRs. Cell . 2019;177:1933-1947. 9. Lüscher C, Slesinger PA. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat Rev Neurosci . 2010;11:301-315. 10. Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol . 2002;366:381-416. 11. Zhang S, et al. Structure, function and drug discovery of GPCR signaling. Mol Biomed . 2023;4:32. 12. Nestler EJ. Neuroplasticity in mood and reward circuitry: relevance for psychiatric disorders. Nat Rev Neurosci . 2022;23:521-539. 13. Kroeze WK, Sassano MF, Huang XP, et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat Struct Mol Biol . 2015;22:362-369. 14. Wang S, Ma B, Wu X, et al. Cryo-EM structures of class A GPCRs illuminate drug discovery strategies. Nat Rev Drug Discov . 2024;23:365-383. 15. Walters WP, Wang R. New trends in virtual screening. J Chem Inf Model . 2019;59:360-371. 16. Roth BL. DREADDs for neuroscientists. Neuron . 2016;89:683-694. 17. Drucker DJ. Incretin-based therapies and their emerging psychiatric applications. Nat Rev Endocrinol . 2023;19:615-631. 18. Anderberg RH, Richard JE, Eerola K, et al. GLP-1 receptors in the nucleus accumbens core and shell differentially modulate dopamine, food intake, and cocaine-conditioned place preference. Neuropsychopharmacology . 2017;42:2027-2036. Information & Authors Information Version history Copyright This work is licensed under a Non Exclusive No Reuse License. Authors Metrics & Citations Metrics Article Usage 260views 251downloads Citations Download citation Michael A. S. Guth. Deorphaning GPR149: A testable framework and integrated roadmap for a neuro-metabolic orphan GPCR. Authorea. 08 December 2025. DOI: https://doi.org/10.22541/au.176521343.32119207/v1 DOI: https://doi.org/10.22541/au.176521343.32119207/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu.